Distribution analysis of S-222611 in brain metastases of HER2-positive breast cancer by quantitative imaging mass spectrometry: prospect for antitumor activity of EGFR/HER2/HER4 kinase inhibitor S-222611 against brain metastases

被引：0
|
作者：
Tanaka, Yukari
Hirata, Michinari
Shinonome, Satomi
Matsumoto, Mitsunobu
Nogami, Wataru
Torii, Mikinori
Nezasa, Ken-ichi
Tanaka, Hidekazu
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4085
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
    Jerusalem, Guy
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Farre, Xavier Gonzalez
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R.
    Murthy, Rashmi K.
    Gianni, Lorenzo
    Takano, Toshimi
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb
    Perrin, Christophe
    CANCER DISCOVERY, 2022, 12 (12) : 2754 - 2762
  • [32] Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model
    Nakayama, Akiko
    Takagi, Shinji
    Yusa, Tadashi
    Yaguchi, Masahiro
    Hayashi, Akira
    Tamura, Toshiya
    Kawakita, Youichi
    Ishikawa, Tomoyasu
    Ohta, Yoshikazu
    JOURNAL OF CANCER, 2013, 4 (07): : 557 - 565
  • [33] Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients
    Renata Duchnowska
    Jacek Jassem
    Chirayu Pankaj Goswami
    Murat Dundar
    Yesim Gökmen-Polar
    Lang Li
    Stephan Woditschka
    Wojciech Biernat
    Katarzyna Sosińska-Mielcarek
    Bogumiła Czartoryska-Arłukowicz
    Barbara Radecka
    Zorica Tomasevic
    Piotr Stępniak
    Konrad Wojdan
    George W. Sledge
    Patricia S. Steeg
    Sunil Badve
    Journal of Neuro-Oncology, 2015, 122 : 205 - 216
  • [34] Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients
    Duchnowska, Renata
    Jassem, Jacek
    Goswami, Chirayu Pankaj
    Dundar, Murat
    Goekmen-Polar, Yesim
    Li, Lang
    Woditschka, Stephan
    Biernat, Wojciech
    Sosinska-Mielcarek, Katarzyna
    Czartoryska-Arlukowicz, Bogumila
    Radecka, Barbara
    Tomasevic, Zorica
    Stepniak, Piotr
    Wojdan, Konrad
    Sledge, George W., Jr.
    Steeg, Patricia S.
    Badve, Sunil
    JOURNAL OF NEURO-ONCOLOGY, 2015, 122 (01) : 205 - 216
  • [35] The efficacy and safety of Tyrosine kinase inhibitors in HER-2 positive breast cancer with brain metastases: a systematic review and meta analysis
    Yu, Y.
    Zhang, J.
    Huang, K.
    Lin, Y.
    Song, C.
    BREAST, 2021, 56 : S41 - S41
  • [36] CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM)
    McArthur, Heather
    Beal, Kathryn
    Halpenny, Darragh
    Henrich, Micaela
    Modi, Shanu
    Patil, Sujata
    Young, Robert
    Kaley, Thomas
    Merghoub, Taha
    Barker, Christopher
    Wong, Phillip
    Hamilton, Nicola
    Hudis, Clifford
    Wolchok, Jedd
    Norton, Larry
    CANCER RESEARCH, 2017, 77
  • [37] EVALUATION OF TUCATINIB FOR HER2-POSITIVE BREAST CANCER PATIENTS WITH BRAIN METASTASES: A UNITED STATES-BASED COST-EFFECTIVENESS ANALYSIS
    Dong, L.
    Nian, D.
    Huang, Y.
    Lin, S.
    Zhong, L.
    Xu, X.
    VALUE IN HEALTH, 2021, 24 : S9 - S9
  • [38] Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis
    Dong, Liangliang
    Lin, Shen
    Zhong, Lixian
    Nian, Dongni
    Li, Yiyuan
    Wang, Rixiong
    Zhou, Wei
    Weng, Xiuhua
    Xu, Xiongwei
    CLINICAL BREAST CANCER, 2022, 22 (01) : E21 - E29
  • [39] Ado-trastuzumab emtansine (T-DM1) is effective against established HER2-positive breast cancer brain metastases in mice
    Askoxylakis, V.
    Ferraro, G.
    Kodack, D.
    Badeaux, M.
    Jain, R.
    CANCER RESEARCH, 2016, 76
  • [40] Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy
    Murrell, Donna H.
    Hamilton, Amanda M.
    Mallett, Christiane L.
    van Gorkum, Robbert
    Chambers, Ann F.
    Foster, Paula J.
    TRANSLATIONAL ONCOLOGY, 2015, 8 (03) : 176 - 184
12345